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SUMMARY 24 
This paper aimed to identify the dietary and non-dietary determinants of docosahexaenoic acid 25 
(DHA) levels in umbilical cord blood at delivery. DHA was measured in cord blood plasma 26 
phospholipids of 1571 participants from the DOMInO (DHA to Optimize Mother Infant Outcome) 27 
randomized controlled trial. Socioeconomic, lifestyle and clinical data relating to the mother and 28 
current pregnancy were obtained from all women and their relationships with cord blood DHA 29 
assessed. DHA concentrations in the cord plasma phospholipids at delivery covered a 3-4 fold range 30 
in both control and DHA groups. The total number of DHA-rich intervention supplement capsules 31 
consumed over the course of pregnancy and gestational age at delivery individually explained 21% 32 
and 16% respectively of the variation in DHA abundance in the cord blood plasma phospholipids at 33 
delivery, but no other clinical or life-style factors explored in this study could account for >2% of 34 
the variation. Indeed, more than 65% of the variation remained unaccounted for even when all 35 
factors were included in the analysis. These data suggest that factors other than maternal DHA 36 
intake have an important role in determining cord blood DHA concentrations at delivery, and may 37 
at least partially explain the variation in the response of infants to maternal DHA supplementation 38 
reported in published trials.  39 
 40 
 41 
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INTRODUCTION 44 
The omega-3 long chain polyunsaturated fatty acid (n-3 LCPUFA), docosahexanoic acid (DHA, 45 
22:6n-3) plays a critical role in development, and an adequate supply of this fatty acid during the 46 
period of rapid growth in late fetal and early postnatal life is essential for optimal development of a 47 
number of key organ systems [1, 2]. The accumulation of DHA in fetal tissues occurs 48 
predominately during the last trimester of pregnancy and continues through the first year of life. 49 
Studies that have determined fatty acid abundance in the umbilical cord blood at delivery have 50 
shown that levels of n-3 LCPUFA, in particular DHA, are higher in the umbilical cord blood (a 51 
marker of fetal supply) compared to the levels of the equivalent fatty acids in the maternal 52 
circulation [1, 3]. This apparent biomagnification is reported to be a result of both preferential 53 
transfer of DHA by the placenta and fetal uptake/metabolism to ensure that the fetal supply of DHA 54 
is maintained even when maternal dietary intake is low [3].  55 
 56 
While the fetus has the capacity for DHA synthesis from the 18-carbon precursor, alpha-linoleic 57 
acid (ALA) and DHA metabolism, the prevailing view is that the principal determinant of DHA 58 
supply to the developing fetus in healthy pregnancies is the DHA intake of the mother[4-6]. 59 
However, studies that have measured cord blood fatty acids have also consistently demonstrated a 60 
high degree of heterogeneity in the DHA content of cord blood phospholipids between individual 61 
women, even when DHA intake is similar [5, 7, 8]. This has led to the suggestion that factors other 62 
than nutritional intake also play an important role in determining cord blood DHA content, and 63 
therefore the delivery of DHA to the developing fetus. Previous studies, albeit most with small 64 
sample sizes, have reported that cord blood DHA levels are related to several non-dietary factors, 65 
including parity [9], maternal and fetal genotype in relation to the desaturase enzymes (FADS1 and 66 
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2) [10] and maternal smoking and alcohol intake [11].  However, these factors only accounted for a 67 
small proportion of the variation in cord blood DHA, and no studies have been able to adequately 68 
account for the variability in cord blood DHA concentrations. Given the importance of DHA for 69 
fetal development, understanding the determinants of fetal DHA status has clear clinical relevance. 70 
 71 
The DOMInO trial is the largest randomized controlled trial to date to investigate the effect of 72 
maternal DHA-supplementation during the second half of pregnancy on neurodevelopmental 73 
outcomes in the children [12] and cord blood samples were obtained from 1571 of these women at 74 
delivery. Detailed sociodemographic, pregnancy and neonatal health information was collected 75 
from all DOMInO participants, including maternal smoking, maternal BMI at study entry, intake of 76 
(non-DHA containing) dietary supplements, maternal education, parity, pregnancy complications 77 
(pre-eclampsia, gestational diabetes mellitus (GDM), induction), caesarean delivery, gestational age 78 
at delivery, birth weight and infant sex. In this paper, we have used the large and well-characterised 79 
DOMInO study population to report the effect of maternal DHA supplementation on the fatty acid 80 
composition of the cord blood and to explore the relationships between the factors listed above and 81 
cord blood DHA levels in an attempt to explain differences in DHA abundance in the umbilical 82 
cord blood at delivery.  83 
 84 
METHODS 85 
Participants 86 
Women with singleton pregnancies at less than 21 weeks' gestation from 5 perinatal centres in 87 
Australia were enrolled in a double-blinded multi-centre randomized controlled trial [12]. Women 88 
were excluded if they were already taking a prenatal supplement containing DHA, their fetus had a 89 
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known major abnormality, they had a bleeding disorder in which tuna oil was contraindicated, were 90 
taking anticoagulant therapy, had a documented history of drug or alcohol abuse, were participating 91 
in another fatty acid trial, were unable to give written informed consent, or if English was not the 92 
main language spoken at home. Approval was granted by the local institutional review boards 93 
(human research ethics committees) of each centre and written informed consent was obtained from 94 
each participant. 95 
 96 
Experimental design  97 
Women were randomly assigned a unique study number corresponding to either the DHA or 98 
Control group through a computer-driven telephone randomization service according to an 99 
independently generated randomization schedule, with balanced variable-sized blocks. Stratification 100 
was by centre and parity (first birth vs subsequent birth). Baseline characteristics, including 101 
maternal age, weight, highest level of education, occupation, smoking status, and intake of (non-102 
DHA containing) dietary supplements were recorded. Mothers were classified as smokers if they 103 
smoked at trial entry or leading up to pregnancy and non-smokers otherwise.  104 
Women allocated to the DHA group were asked to consume three 500 mg/d capsules of DHA-rich 105 
fish oil concentrate, providing 800 mg/d of DHA and 100 mg/d of eicosapentaenoic acid (EPA, 106 
20:5n-3; Incromega 500 TG, Croda Chemicals, East Yorkshire, England); and women in the control 107 
group were asked to take three 500 mg/d vegetable oil capsules without DHA which contained a 108 
blend of oils designed to match the polyunsaturated, monounsaturated and saturated fatty acid 109 
profile of the typical Australian diet [13].  All capsules were similar in size, shape, and colour and 110 
were donated by Efamol, Surrey, England. All participants as well as medical, nursing, clinical and 111 
laboratory staff were unaware of the treatment group allocation for the entire duration of the trial. 112 
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Women were asked to take their assigned capsules daily from study entry until birth, and to return 113 
any unused capsules, which enabled the total number of DHA-rich intervention supplement 114 
capsules consumed over the course of pregnancy and compliance to be assessed. Information on 115 
pregnancy and neonatal outcomes was collected from medical records. These outcomes included: 116 
gestational age at delivery, caesarean section vs vaginal delivery, clinical diagnosis of pre-117 
eclampsia, clinical diagnosis of gestational diabetes (GDM), induction, birth weight and infant sex.  118 
 119 
At the time of delivery, samples of cord blood were collected from 1571 women (798 in the DHA 120 
group and 773 in the control group) for the measurement of the fatty acid composition of plasma 121 
phospholipids. The baseline characteristics, pregnancy and neonatal outcomes for the women from 122 
whom cord blood was collected are presented in Table 1.  123 
 124 
Fatty acid analyses 125 
Whole blood was collected into lithium heparin tubes and erythrocyte and plasma fractions 126 
separated by centrifugation. Plasma was stored at -20°C at each separate site and all plasma samples 127 
were then transported to Adelaide on dry ice for analysis. Cord plasma phospholipids were analysed 128 
according to previously established methods [14]. Briefly, plasma lipids were extracted in 129 
chloroform:methanol, the chloroform layer removed and evaporated under nitrogen, and 130 
phospholipids separated by thin-layer chromatography. Phospholipids were methylated in 1% 131 
H2SO4 in methanol at 70°C for 3h. The resulting methyl esters were extracted into n-heptane and 132 
dehydrated in anhydrous Na2SO4. Fatty acid methyl esters were separated and quantified using a 133 
Hewlett-Packard 5880 gas chromatograph equipped with a 50m capillary column coated with BPX-134 
70 (0.25micron film thickness, SGE PtyLtd., Victoria, Australia) using conditions described in 135 
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detail previously [14] and identified based on retention time to authentic lipid standards obtained 136 
from Nucheck Prep Inc (Elysian, MN). For statistical purposes, fatty acids at concentrations lower 137 
than the limit of detection (0.05%) were allocated a set value of 0.025% (half the limit of detection). 138 
The abundance of all fatty acids was expressed as a percentage of total fatty acids in the sample. 139 
 140 
Statistical Analyses 141 
Cord plasma phospholipid fatty acid concentrations were compared between treatment groups using 142 
t-tests. Concentrations were log transformed prior to analysis to achieve normality, with the 143 
exception of total saturates, arachidonic acid (AA, 20:4 n-6) and total n-6 PUFA, which did not 144 
require any transformation.  145 
 146 
Log transformed cord plasma phospholipid DHA abundance values were analyzed using linear 147 
regression models and effects were exponentiated to give geometric mean cord plasma 148 
phospholipid DHA abundance. The predictor variables considered in the regression models were: 149 
total number of DHA-rich intervention supplement capsules consumed over the course of 150 
pregnancy (0 for women in the control group), maternal smoking status, maternal BMI at study 151 
entry, parity, maternal intake of (non-DHA containing) dietary supplements during pregnancy, 152 
maternal education, gestational age at delivery, caesarean section vs vaginal delivery, clinical 153 
diagnosis of pre-eclampsia, clinical diagnosis of GDM, induction, birthweight z-score and infant 154 
sex. In additional analyses, the levels of other quantitatively important fatty acids in the cord blood 155 
(saturated fatty acids, monounsatured fatty acids, LA and AA) were also considered as predictor 156 
variables. The relationship of LA and AA with gestational age was also examined using linear 157 
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regression models. Both univariable and multivariable analyses were performed. All tests were two-158 
sided and statistical significance was assessed at the 0.05 level. 159 
 160 
RESULTS 161 
Effect of maternal n-3 LCPUFA supplementation on fatty acid composition of cord blood 162 
phospholipids 163 
The fatty acid composition of the cord blood plasma phospholipids for the DHA and control groups 164 
is shown in Table 2. Independent of treatment group, AA and DHA were the most abundant n-6 165 
and n-3 LCPUFA in the cord blood phospholipids. Cord blood from DHA-supplemented mothers 166 
had significantly higher proportions of the three principal n-3 LCPUFA, EPA, docosapentaenoic 167 
acid (DPA, 22:5 n-3) and DHA) and a significantly lower proportion of AA compared with cord 168 
blood from mothers in the control group (Table 2). The cord blood from the mothers in the DHA 169 
group also contained a slightly (40%) higher proportion of LA compared with the control group. 170 
There was no evidence of a difference in the proportion of total saturated or total monounsaturated 171 
fatty acids in the cord blood plasma phospholipids between the DHA and control groups. 172 
 173 
Determinants of cord blood DHA concentrations 174 
Cord blood phospholipid DHA abundance ranged from 3.4% to 11.8% of total fatty acids in the 175 
control group (median 6.1%), and 3.1% to 13.7% of total fatty acids in the DHA group (median 176 
7.5%). The strongest predictors of cord-blood DHA abundance in univariable analyses were total 177 
number of DHA-rich intervention capsules consumed during pregnancy (R2=0.2138, P<0.0001) and 178 
gestational age at delivery (R2=0.1612, P<0.0001). The importance of DHA supplement intake and 179 
gestational age was confirmed by the multivariable analysis (Table 3). These predictors remained 180 
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highly significant in the multivariable model (P<0.0001 in both cases) and the R2 of 0.35 from the 181 
model containing all predictors (Table 3) was comparable to the R2 of 0.33 from the model 182 
containing only intake of DHA-rich supplement capsules and gestational age at delivery (data not 183 
shown).   184 
 185 
The proportion of DHA in cord blood phospholipids increased with increasing gestational age 186 
(P<0.0001), such that for every one week increase in gestation, there was an estimated 7.48% (95% 187 
CI 6.61% to 8.36%) relative increase in the mean abundance of DHA in the cord blood 188 
phospholipids (Table 3). However, there was considerable variability in cord blood DHA 189 
abundance in both the DHA and Control groups at any given gestational age (Figure 1).  190 
 191 
Maternal factors significantly related to cord blood DHA abundance in univariable analyses 192 
included parity (R2=0.0074), maternal intake of (non-DHA containing) dietary supplements 193 
(R2=0.0044), maternal BMI at study entry (R2=0.0028), Caesarean section (R2=0.0034), clinical 194 
diagnosis of GDM (R2=0.0161) and induction (R2=0.0104). Infant sex was also a significant 195 
predictor of cord blood DHA (R2=0.0031). However, each of these variables explained less than 2% 196 
of the variation in DHA concentrations (Table 3). There was no significant relationship between 197 
cord blood DHA and maternal smoking status, maternal education, birth weight z-score or clinical 198 
diagnosis of pre-eclampsia (Table 3).  199 
 200 
Association of cord blood DHA with other cord blood fatty acids 201 
The levels of DHA in the cord blood were positively related to total saturated fatty acids 202 
(R2=0.00470, P=0.0065), and inversely related to LA (R2=0.0885, P<0.0001) and AA (R2=0.0152, 203 
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P<0.0001) content in the cord blood at delivery. Monounsaturated fatty acid content was also 204 
inversely related to DHA content, and accounted for ~26% of the variability in DHA levels 205 
(R2=0.2650, P<0.0001). The proportion of LA (P<0.001) and AA (P=0.01) in cord blood 206 
phospholipids decreased with increasing gestational age in both the DHA and control groups; for 207 
every one week increase in gestation, there was an estimated relative decrease of 2.48% (95% CI 208 
1.71% to 3.24%) for LA concentration and an estimated absolute decrease of 0.12% (95% CI 0.03% 209 
to 0.20%) for AA concentration (data not shown).  210 
 211 
DISCUSSION 212 
The major finding of this paper was that despite the availability of a detailed set of maternal and 213 
infant data from over 1500 pregnancies, and inclusion of a large number of clinical and lifestyle 214 
variables in a multivariate analysis, the resulting model explained less than 35% of the variation in 215 
cord blood DHA abundance. The only factors which explained a substantial proportion of the 216 
variation in cord blood DHA were the number of DHA-rich intervention supplements consumed 217 
over the course of pregnancy and gestational age at delivery, which together accounted for ~35% of 218 
the variation. In contrast, all other variables which were significantly related to cord blood DHA, 219 
i.e. maternal BMI, parity and intake of other dietary supplements, maternal diagnosis of GDM, 220 
caesarean section, pregnancy induction and infant sex, each accounted for less than 2% of the 221 
observed variation in cord blood DHA levels. These data suggest more than 65% of the variation in 222 
cord blood DHA is explained by other, as yet unexplored factors, and highlights the need for studies 223 
specifically aimed at elucidating other maternal, placental and fetal determinants of fetal DHA 224 
supply. 225 
 226 
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As expected, supplementing pregnant women with ~800mg of DHA and 100mg EPA per day in the 227 
second half of pregnancy resulted in a significant increase in the n-3 LCPUFA abundance in cord 228 
blood phospholipids at the time of delivery. The relative increase in cord-blood DHA abundance in 229 
the supplemented group was ~23%, which is comparable with the results of other studies of 230 
maternal DHA supplementation using similar doses of DHA [7, 15]. The increase in n-3 LCPUFA 231 
levels in the cord blood of supplemented women was associated with a corresponding decrease in 232 
the n-6 PUFA content. The decrease in total n-6 PUFA concentrations was almost entirely 233 
accounted for by a decrease in the abundance of AA in the supplemented group, the magnitude of 234 
which was approximately equal to the increase in total n-3 LPCUFA (EPA, DPA, DHA) 235 
abundance. This is not unexpected given the competition which exists between the n-3 LCPUFA 236 
and AA for incorporation into plasma phospholipids, such that relative increases in the availability 237 
of n-3 LCPUFA reduce the incorporation of AA into this lipid fraction [16, 17].  238 
 239 
While DHA abundance in the cord blood was increased by supplementation, there was a wide range 240 
(~3-4 fold) in cord blood DHA within each treatment group, and a substantial overlap of cord blood 241 
DHA abundance between control and supplemented women. In addition, while cord blood DHA 242 
levels were positively predicted by the total number of n-3 LCPUFA intervention capsules 243 
consumed during pregnancy, this only accounted for ~21% of the variation in cord blood DHA. It is 244 
possible that the n-3 LCPUFA content of the background diet and n-3 LCPUFA status of the 245 
mother before and during pregnancy, which was not assessed in the DOMInO women, may account 246 
for some of the remaining variation. However, since none of the women were taking n-3 LCPUFA 247 
supplements at the time of trial entry, and the average dietary intake of DHA in Australian women 248 
is <200mg/day [13], the increase in n-3 LCPUFA intake as a result of the 900mg/day n-3 LCPUFA 249 
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supplementation in DOMInO would be expected to substantially exceed the n-3 LCPUFA content 250 
of the background diet for the vast majority of the women. The background dietary intake of n-3 251 
LCPUFA is therefore unlikely to have contributed significantly to this variability. Furthermore, our 252 
finding that the intake of n-3 LCPUFA in the form of supplements cannot fully account for cord 253 
blood DHA abundance confirms the findings of a number of smaller studies [5, 7, 8], and reinforces 254 
the suggestion that factors beyond maternal dietary DHA intake play an important role in 255 
determining fetal DHA levels.  256 
 257 
In addition to maternal n-3 LCPUFA, maternal intakes of other fatty acids in the maternal diet, in 258 
particular n-6 PUFA, may also have contributed to variations in n-3 LCPUFA delivery to the fetus 259 
in late gestation. Higher maternal intakes of n-6 PUFA could have reduced n-3 LCPUFA status in 260 
the mother by increasing competition for cellular incorporation and therefore reduced the 261 
availability of n-3 LCPUFA for placental transfer, which is supported the inverse relationship 262 
between LA and DHA levels in the cord blood observed in the DOMInO women. The fatty acid 263 
composition of the maternal diet preceding and in the early stages of pregnancy also has the 264 
potential to contribute to variations in cord blood DHA content, since these fatty acids would be 265 
deposited in maternal adipose tissue stores, and could be released as rates of lipid turnover increase 266 
in late pregnancy [18]. Detailed assessments of the fatty acid composition of the maternal diet 267 
and/or maternal blood at different stages of pregnancy in future studies may provide additional 268 
insights into their contribution to the variations in fetal DHA supply.  269 
 270 
The only identified variable other than n-3 LCPUFA supplement intake to explain an appreciable 271 
amount of the variation in cord blood DHA was gestational age at delivery, and this accounted for a 272 
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similar proportion of the variation (~16%) as supplement intake. DHA in the cord blood increased 273 
with advancing gestation, and this occurred at the same rate in both the control and supplemented 274 
groups. Increases in DHA abundance in cord blood phospholipids with advancing gestation has also 275 
been reported by others [19, 20]. A number of physiological changes which occur during 276 
pregnancy, including remodelling of the placenta, result in increased efficiency of placental DHA 277 
transport [3], which likely contributes to increases in cord blood DHA across gestation.  While 278 
levels of DHA increased across gestation, the cord blood content of n-6 PUFA, in particular AA, 279 
decreased across this same period, and this may also have contributed to the proportional increase 280 
in cord blood DHA content.  281 
 282 
There was still considerable heterogeneity, however, in cord blood DHA at any given gestational 283 
age that was not fully accounted for by any of the clinical and lifestyle variables which were 284 
assessed, suggesting that other factors which were not measured in DOMInO also make an 285 
important contribution to this variation. The results of this study raise the possibility that 286 
considerable inter-individual differences could exist in maternal, placental and/or fetal fatty acid 287 
metabolism, which could have significant implications for the relationship between maternal DHA 288 
supplementation and fetal DHA supply.  289 
While the fundamental aspects of placenta fatty acid metabolism and transport have been described, 290 
there are few studies that have examined the extent to which are modified by other 291 
dietary/genetic/environmental factors. Variations in the efficiency of placental DHA transfer would 292 
be expected to modulate the relationship between maternal and cord blood DHA levels, and could 293 
potentially account for the greater degree of heterogeneity in DHA concentrations observed in cord 294 
blood as compared with those in the circulation of children and adults. There is evidence of aberrant 295 
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expression of fatty acid binding proteins in pregnancies complicated by GDM and intrauterine 296 
growth restriction [21, 22], but it is unclear to what extent these vary in healthy pregnancies. While 297 
the DOMInO study included largely healthy pregnancies, women with GDM had lower DHA levels 298 
in the cord blood, indicative of impaired placental transfer capacity, which is consistent with 299 
previous studies [23]. Interestingly, pre-eclampsia, which has been associated with altered maternal 300 
lipid metabolism in previous studies, was not a significant predictor of cord blood DHA in this 301 
study, however this may have been due to the relatively small number of pre-eclamptic women 302 
(~3%) in our sample.  303 
 304 
It is important to note that since all fatty acids in the present study were expressed as a percentage 305 
of total lipids, rather than absolute amounts, the proportion of different fatty acids are not 306 
independent of each other, and we cannot entirely exclude the possibility that alterations to cord 307 
blood DHA were secondary to increases or decreases in the levels of other fatty acids. Thus, the 308 
inverse relationship between the level of DHA and monounsaturates in the cord blood, may indicate 309 
that decreases in monounsaturated fatty acid transfer/synthesis contribute to higher DHA content in 310 
cord blood. The positive relationship between DHA and saturated fatty acids, however, appears 311 
more likely to be indicative of an overall increase in the efficiency of placental transfer, since 312 
saturated fatty acids in the fetal circulation are largely derived from de novo synthesis [24].  313 
 314 
Although the fetus can undoubtedly make use of maternal LCPUFA supplies, it also has the 315 
capacity for synthesising LCPUFA from 18 carbon precursors [25]. The inflow of LCPUFA 316 
(dietary and endogenous synthesis) together with possible active uptake of DHA by the placenta 317 
and fetal synthesis could all contribute to the higher DHA in cord vs maternal blood. Thus, 318 
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variations in any of these physiological/biochemical processes could contribute to the large 319 
variations in cord blood seen in this study.  320 
 321 
Another factor which is increasingly being associated with fatty acid concentrations in both adults 322 
and infants is the genotype of individuals in relation to the genes encoding the two key desaturase 323 
enzymes in the PUFA metabolic pathway, FADS1 and FADS2. In a study of over 2000 mother-324 
infant pairs from the ALSPAC study, both maternal and infant FADS genotype were related to 325 
DHA abundance in the umbilical venous cord blood at delivery [10]. However, while it is possible 326 
that the FADS genotype of the mother and child, which were not assessed in DOMInO, could have 327 
contributed to differences in cord blood fatty acid composition on, this is unlikely to be a major 328 
factor, given that previous studies have suggested that maternal/child FADS genotype accounts for 329 
only ~1% of the variation in cord blood n-3 LCPUFA concentrations [10].  330 
 331 
Conclusion  332 
In conclusion, we have reported cord blood DHA abundance for >1500 women from the n-3 333 
LCPUFA supplementation DOMInO trial, and demonstrated a 3 to 4-fold variation in cord blood 334 
DHA concentration within each treatment group. In spite of the inclusion of detailed clinical and 335 
lifestyle data from the DOMInO women in our analyses, we were able to explain less than 35% of 336 
this variation and, therefore, the factors which explain the remaining ~65% variation in cord blood 337 
DHA remain to be defined. The findings of this study have relevance to current dietary 338 
recommendations in relation to DHA intakes in pregnant women, since they suggest that the same 339 
level of maternal DHA intake can translate into markedly different cord blood levels of this fatty 340 
acid. In addition, these data may help explain previous reports of variability in fetal and postnatal 341 
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outcomes following maternal n-3 LCPUFA supplementation. A more complete understanding of 342 
the factors which determine the fatty acid transfer capacity of the placenta, the extent to which this 343 
varies in healthy pregnancies, and the potential impact of maternal/fetal genotype on the response to 344 
maternal n-3 LCPUFA will be valuable in assisting us in understanding the most important 345 
determinants of fetal n-3 LCPUFA supply and, ultimately, designing personalised supplementation 346 
regimens. 347 
 348 
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Table 1. Characteristics of women with cord blood samples by treatment group 425 
Characteristic DHA (n=798) Control (n=773) Total (n=1571) 
Intake of DHA Supplements: Median (IQ 
range) 
360.0 (303.0-402.0) 0.0 (0.0-0.0) 0.0 (0.0-360.0) 
Smoker: N (%) 232 (29.1) 236 (30.5) 468 (29.8) 
BMI at Study Entry: Median (IQ range) 26.4 (23.5-30.8) 26.3 (23.0-30.6) 26.4 (23.3-30.7) 
Nulliparous: N (%) 311 (39.0) 314 (40.6) 625 (39.8) 
Consumed non-DHA Dietary 
Supplements: N (%) 
437 (54.8) 421 (54.5) 858 (54.6) 
Completed Secondary Education: N (%) 505 (63.3) 507 (65.6) 1012 (64.4) 
Completed Further Education: N (%) 547 (68.5) 546 (70.6) 1093 (69.6) 
Gestational Age at Birth: Median (IQ 
range) 
39.9 (39.0-40.7) 39.6 (38.7-40.4) 39.7 (38.9-40.6) 
Caesarean Section: N (%) 210 (26.3) 218 (28.2) 428 (27.2) 
Clinical Diagnosis of Pre-eclampsia: N 
(%) 
23 (2.9) 22 (2.8) 45 (2.9) 
Clinical Diagnosis of GDM: N (%) 58 (7.3) 49 (6.3) 107 (6.8) 
Induction: N (%) 264 (33.1) 212 (27.4) 476 (30.3) 
Birthweight Z-Score: Mean (SD) 0.3 ( 1.0) 0.3 ( 1.0) 0.3 ( 1.0) 
Infant Male Sex: N (%) 402 (50.4) 373 (48.3) 775 (49.3) 
 426 
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Table 2. Comparison of fatty acid composition of cord blood phospholipids in the DHA and 427 
placebo groups# 428 
 429 
Fatty Acid (% total 
fatty acids) 
DHA 
(n=798) 
Control 
(n=773) P-value 
16:0 29.9 (29.1-30.7) 29.9 (29.1-30.6) 0.54 
18:0 15.2 (14.3-15.9) 15.1 (14.2-16.0) 0.58 
Total Saturates 48.3 (47.5-49.4) 48.3 (47.6-49.7) 0.29 
18:1n-9 7.7 (7.0-8.5) 7.6 (6.9-8.3) 0.11 
Total Monounsaturates 12.5 (11.5-13.6) 12.5 (11.4-13.6) 0.96 
LA,  18:2n-6 7.4 (6.5-8.4) 7.1 (6.2-8.2) 0.0042 
AA, 20:4n-6 14.8 (13.8-16.2) 16.6 (15.4-17.7) <.0001 
Total n-6 PUFA 29.3 (27.7-30.6) 30.7 (29.6-31.9) <.0001 
EPA, 20:5n-3 0.5 (0.3-0.7) 0.3 (0.2-0.3) <.0001 
DPA, 22:5n-3 0.5 (0.4-0.6) 0.5 (0.3-0.6) <.0001 
DHA, 22:6n-3 7.5 (6.3-8.9) 6.1 (5.2-7.2) <.0001 
Total n-3 PUFA 8.8 (7.4-10.3) 7.1 (6.1-8.3) <.0001 
    
#all values expressed as median (interquartile range) % total fatty acids430 
24 
 
Table 3. Effect of potential predictors on cord blood DHA content 431 
Predictor Comparison Univariable Analyses   Multivariable Analysis  
 
 Effect (95% CI)+ P-value R2 Effect  (95% CI)* P-value 
Maternal Factors        
Intake of DHA Supplements Increase of 1 week’s intake^ 1.0134 (1.0121, 1.0147) <.0001 0.2138 1.0122 (1.0109, 1.0134) <.0001 
Smoking status pre-pregnancy Smoker vs non-smoker 0.9787 (0.9527, 1.0055) 0.1179 0.0016 1.0034 (0.9796, 1.0276) 0.7834 
BMI at study entry Increase of 1kg/m2 0.9978 (0.9958, 0.9999) 0.0376 0.0028 1.0000 (0.9982, 1.0019) 0.9690 
Parity ≥1 vs 0 0.9572 (0.9335, 0.9816) 0.0007 0.0074 0.9812(0.9597, 1.0032) 0.0929 
Intake of (non-DHA) dietary 
Supplements 
Supplements vs none 1.0339 (1.0086, 1.0598) 0.0083 0.0044 1.0141 (0.9927, 1.0359) 0.1976 
Completion of Secondary Education Completed vs not completed 1.0235 (0.9975, 1.0502) 0.0771 0.0020 1.0239 (1.0005, 1.0478) 0.0451 
Completion of Further Education Completed vs not completed 1.0098 (0.9830, 1.0372) 0.4780 0.0003 1.0043 (0.9814, 1.0278) 0.7144 
Pregnancy Factors       
Gestational Age at birth Increase of 1 week 1.0748 (1.0661, 1.0836) <.0001 0.1612 1.0612 (1.0528, 1.0697) <.0001 
Caesarean Section Caesarean vs no caesarean 0.9680 (0.9416, 0.9952) 0.0213 0.0034 0.9994 (0.9760, 1.0234) 0.9625 
Clinical Diagnosis of pre-eclampsia Pre-eclampsia vs no  pre-eclampsia 0.9843 (0.9141, 1.0600) 0.6758 0.0001 1.0357 (0.9709, 1.1049) 0.2868 
Clinical Diagnosis of GDM Diabetes vs no diabetes 0.8818 (0.8400, 0.9258) <.0001 0.0161 0.9326 (0.8941, 0.9727) 0.0012 
Induction Induced vs not induced 1.0568 (1.0290, 1.0855) <.0001 0.0104 1.0042 (0.9804, 1.0285) 0.7342 
Infant Factors       
Birth weight Z-Score Increase of 1 SD 0.9906 (0.9784, 1.0030) 0.1367 0.0014 0.9856 (0.9750, 0.9962) 0.0082 
Infant Sex Female vs male 0.9728 (0.9491, 0.9971) 0.0284 0.0031 0.9753 (0.9553, 0.9956) 0.0175 
* R2=0.3467 for multivariable model  432 
^ Equates to 21 treatment capsules each containing 800mg DHA and 100mg EPA 433 
+
 Effects have been back-transformed to give ratios of geometric means on the original scale 434 
435 
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FIGURE LEGENDS 436 
Figure 1. The relationship between DHA content in the cord blood phospholipids (expressed as a percentage of total fatty acids) and 437 
gestational age at delivery in the Control (open circles) and DHA (closed circles) groups. Lines are estimated geometric mean cord blood 438 
DHA concentrations in the DHA group (solid line) and control group (dashed line). 439 
